Souhaitez-vous accéder aux communiqués récents ?

Science 37 Wins Awards for Excellence in Clinical Trial Delivery, Site Innovation, and Enrollment Acceleration

Torrance, CA, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Christina Wang, MD, and Lynda Polgreen, MD, MS, investigators at The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, have...

Science 37 announces the successful completion of its third FDA inspection with a No Action Indicated (NAI) categorization.

Science 37 and Catalent announce a strategic partnership enabling direct-to-patient investigational medicinal product (IMP) delivery for clinical research.

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing...

Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes...

Company on track to commence U.S. clinical studies in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX, April 08, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:...

Science 37 announces the appointment of Tyler Van Horn as Chief Executive Officer.

Intelligent Fingerprinting Drug Screening System on path to FDA 510(k) submission, expected in the fourth calendar quarter of 2024 INBS will include data from recent PK study alongside results of...

PK Study Successfully Demonstrates that Fingerprint Sweat Provides Reliable Sample for Drug Detection FDA 510(k) Clearance Would Enable the Introduction of INBS’ Technology to the US in 2025 NEW...